AstraZeneca's Roxadustat Receives China Approval
December 18 2018 - 4:55AM
Dow Jones News
By Carlo Martuscelli
AstraZeneca PLC (AZN.LN) said Tuesday that its drug roxadustat
has been approved in China as a treatment for patients who have
chronic kidney disease and are on dialysis.
The company said its partner FibroGen China, a subsidiary of
FibroGen Inc. (FGEN), has received marketing authorization from the
Chinese National Medical Products Administration for orally
administered roxadustat. The two companies are collaborating on the
development and commercialization of the drug in China.
The Anglo-Swedish drugmaker said it will be responsible for
bringing the drug to market in the country, while FibroGen will
manage the processes of manufacturing, regulation and continued
research.
The company said it expects to launch roxadustat in China in the
second half of 2019.
Write to Carlo Martuscelli at carlo.martuscelli@dowjones.com
(END) Dow Jones Newswires
December 18, 2018 04:40 ET (09:40 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
AstraZeneca (NYSE:AZN)
Historical Stock Chart
From Mar 2024 to Apr 2024
AstraZeneca (NYSE:AZN)
Historical Stock Chart
From Apr 2023 to Apr 2024
